TITLE

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak

AUTHOR(S)
Sung, J. J. Y.; Wu, A.; Joynt, G. M.; Yuen, K. Y.; Lee, N.; Chan, P. K. S.; Cockram, C. S.; A. T. Ahuja; Yu, L. M.; Wong, V. W.; Hui, D. S. C.
PUB. DATE
May 2004
SOURCE
Thorax;May2004, Vol. 59 Issue 5, p414
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The outcome is reported of a prospective uncontrolled study based on a stepwise treatment protocol during an outbreak of severe acute respiratory syndrome (SARS) in Hong Kong. Method: One hundred and thirty eight patients were treated with broad spectrum antibiotics, a combination of ribavirin and low dose corticosteroid, and then intravenous high dose methylprednisolone according to responses. Sustained response to treatment was defined as (1) defervescence for &seg;4 consecutive days, (2) resolution of lung consolidation by >25%, and (3) oxygen independence by the fourth day without fever. Patients with defervescence who achieved either criterion 2 or 3 were classified as partial responders. Patients who fell short of criteria 2 and 3 were non-responders. Results: Laboratory confirmation of SARS coronavirus infection was established in 132 (95.7%). None responded to antibiotics but 25 (18.1%) responded to ribavirin + low dose corticosteroid. Methylprednisolone was used in 107 patients, of whom 95 (88.8%) responded favourably. Evidence of haemolytic anaemia was observed in 49 (36%). A high level of C-reactive protein at presentation was the only independent predictor for use of methylprednisolone (odds ratio 2.18 per 10 mg/dl increase, 95% confidence interval 1.12 to 4.25, p=0.02). Thirty seven patients (26.8%) required admission to the intensive care unit and 21 (15.2%) required invasive mechanical ventilation. There were 15 deaths (mortality rate 10.9%), most with significant co-morbidities, whereas 122 (88.4%) had been discharged home 4 months after the outbreak onset. Conclusion: The use of high dose pulse methylprednisolone during the clinical course of a SARS outbreak was associated with clinical improvement, but randomized controlled trials are needed to ascertain its efficacy in this condition.
ACCESSION #
13372510

 

Related Articles

  • Nucleocapsid Protein as Early Diagnostic Marker for SARS. Xiao-Yan Che; Wei Hao; Yadi Wang; Biao Di; Kai Yin; Yin-Chao Xu; Chang-Sen Feng; Zhuo-Yue Wan; Vincent C.C. Cheng; Kwok-Yung Yuen // Emerging Infectious Diseases;Nov2004, Vol. 10 Issue 11, p1947 

    Serum samples from 317 patients with severe acute respiratory syndrome (SARS) were tested for the nucleo-capsid (N) protein of SARS-associated coronavirus, with sensitivities of 94% and 78% for the first 5 days and 6-10 days after onset, respectively. The specificity was 99.9%. N protein can be...

  • SARS: Systematic Review of Treatment Effects. Stockman, Lauren J.; Bellamy, Richard; Garner, Paul // PLoS Medicine;Sep2006, Vol. 3 Issue 9, pe343 

    Background:The SARS outbreak of 2002-2003 presented clinicians with a new, life-threatening disease for which they had no experience in treating and no research on the effectiveness of treatment options. The World Health Organization (WHO) expert panel on SARS treatment requested a systematic...

  • An Outbreak of Middle East Respiratory Syndrome Coronavirus Infection in South Korea, 2015. Jun Yong Choi // Yonsei Medical Journal;Sep2015, Vol. 56 Issue 5, p1174 

    No abstract available.

  • Coalition Forces and the Fog of War. Davies, Kevin // Bio-IT World;May2003, Vol. 2 Issue 5, p6 

    Discusses the emergence of research coalition forces coordinated by the U.S. Centers for Disease Control and Prevention, following the outbreak of SARS disease in 2003. Origin of the disease; Use of virochips technology in revealing the nature of the disease; Concerns raised by the disease;...

  • Update: Severe Acute Respiratory Syndrome—United States, May 21, 2003.  // JAMA: Journal of the American Medical Association;6/11/2003, Vol. 289 Issue 22, p2932 

    Updates the occurrence of severe acute respiratory syndrome (SARS) world wide and in the United States as of May 21, 2003. Modification of the U.S. SARS case definition defining criteria for exclusion of previously reported cases and for reporting travel-associated cases for surveillance...

  • Infection Control in Mass-Casualty Respiratory Care: Research Needs and Future Directions. Daugherty, Elizabeth L.; Rubinson, Lewis // Respiratory Care;Jul2009, Vol. 54 Issue 7, p841 

    The article focuses on the study conducted by S. M. Khoo and colleagues on the strategies to protect patients and clinicians from hospital-acquired infection by the severe acute respiratory syndrome (SARS) coronavirus in Singapore. The authors indicate that Khoo identified the efficacy of...

  • Corticosteroid use in SARS: increased ICU admission, mortality.  // Reactions Weekly;9/24/2005, Issue 1070, p4 

    Reports on the effects of corticosteroid use on patients with severe acute respiratory syndrome (SARS) according to the results of a retrospective cohort study conducted in Hong Kong, China. Number of SARS patients who died after they had received corticosteroid therapy of various dosages.

  • Anti-infectives: Targeting SARS. Jones, Susan // Nature Reviews Microbiology;Sep2004, Vol. 2 Issue 9, p686 

    The article reports developments on the study on severe acute respiratory virus (SARS-CoV) as published in the Proceedings of the National Academy of Sciences in the U.S. Based on the report, fifteen compounds that are potent against the SARS-CoV were identified. They include the ribavirin and...

  • Severe Acute Respiratory Syndrome-associated Coronavirus in Lung Tissue. Mazzulli, Tony; Farcas, Gabriella A.; Poutanen, Susan M.; Willey, Barbara M.; Low, Donald E.; Butany, Jagdish; Asa, Sylvia L.; Kain, Kevin C. // Emerging Infectious Diseases;Jan2004, Vol. 10 Issue 1, p20 

    Efforts to contain severe acute respiratory syndrome (SARS) have been limited by the lack of a standardized, sensitive, and specific test for SARS-associated coronavirus (CoV). We used a standardized reverse transcription-polymerase chain reaction assay to detect SARS-CoV in lung samples...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics